Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | DUT | P33316 | 5/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.36 |
| ▸ | BAD | Q92934 | 1/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | RHEB | Q15382 | 1/20 | 0.35 |
| ▸ | BCL2 | P10415 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | EIF4EBP1 | Q13541 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16632486 | 0.92 | L3MBTL1 (0.53) | L3MBTL1DUTMCL1BCL2L1BAD | |
| SCHEMBL16632420 | 0.90 | L3MBTL1 (0.47) | L3MBTL1DUTEIF4EBP1 | |
| SCHEMBL16632412 | 0.86 | L3MBTL1 (0.49) | L3MBTL1CYP1A2CYP2C19EIF4EBP1 | |
| SCHEMBL16632594 | 0.81 | L3MBTL1 (0.48) | L3MBTL1DUTMCL1BADLMNA | |
| SCHEMBL16632595 | 0.81 | L3MBTL1 (0.44) | L3MBTL1DUTEIF4EBP1 | |
| SCHEMBL16632334 | 0.81 | L3MBTL1 (0.45) | L3MBTL1DUTRHEB | |
| SCHEMBL16632282 | 0.80 | L3MBTL1 (0.47) | L3MBTL1MCL1BCL2L1BADCYP1A2 | |
| SCHEMBL16632555 | 0.80 | L3MBTL1 (0.47) | L3MBTL1DUTCYP1A2CYP2C19EIF4EBP1 | |
| SCHEMBL16632625 | 0.79 | L3MBTL1 (0.42) | L3MBTL1DUTMCL1BADNPC1 | |
| SCHEMBL16632387 | 0.79 | L3MBTL1 (0.43) | L3MBTL1DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382245-B2 | Compounds and methods for treating HIV infections | YALE UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | POLM, POLRMT, DHFR | L3MBTL1 879/4885DUT 19/4885MCL1 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.